SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-077093
Filing Date
2024-07-02
Accepted
2024-07-02 08:14:02
Documents
17
Period of Report
2024-07-02
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2418712d1_8k.htm   iXBRL 8-K 27358
2 EXHIBIT 99.1 tm2418712d1_ex99-1.htm EX-99.1 29451
6 GRAPHIC tm2418712d1_ex99-1img001.jpg GRAPHIC 17096
7 GRAPHIC tm2418712d1_ex99-1img002.jpg GRAPHIC 23785
8 GRAPHIC tm2418712d1_ex99-1img003.jpg GRAPHIC 27599
  Complete submission text file 0001104659-24-077093.txt   334447

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20240702.xsd EX-101.SCH 3021
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20240702_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20240702_pre.xml EX-101.PRE 22363
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2418712d1_8k_htm.xml XML 3791
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 241092954
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)